Elizabeth D. Hood

Elizabeth D. Hood

Auto-generated profile, based on publicly available information

Elizabeth D. Hood

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in ACS Nano
Verified
Journal Article
Closed access
JPJungwook Paek
Jungwook Paek
SPSunghee E. Park
Sunghee E. Park
QLQiaozhi Lu
Qiaozhi Lu
KPKyu-Tae Park
Kyu-Tae Park
MCMinseon Cho
Minseon Cho
DHDongeun Huh
Dongeun Huh

29 September 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
PGPatrick Glassman
Patrick Glassman
EHElizabeth D. Hood
Elizabeth D. Hood
LFLaura T. Ferguson
Laura T. Ferguson
ZZZongmin Zhao
Zongmin Zhao
DSDon L. Siegel
Don L. Siegel
VMVladimir R. Muzykantov
Vladimir R. Muzykantov

1 April 2014 in Biomaterials
Verified
Journal Article
Closed access
EHElizabeth D. Hood
Elizabeth D. Hood
MCMichael Chorny
Michael Chorny
CGColin F. Greineder
Colin F. Greineder
IAIvan S. Alferiev
Ivan S. Alferiev
RLRobert J. Levy
Robert J. Levy
VMVladimir R. Muzykantov
Vladimir R. Muzykantov

10 March 2022 in ACS Nano
Verified
Journal Article
Closed access
LFLaura T. Ferguson
Laura T. Ferguson
EHElizabeth D. Hood
Elizabeth D. Hood
TSTea Shuvaeva
Tea Shuvaeva
VSVladimir V. Shuvaev
Vladimir V. Shuvaev
MBMaria C. Basil
Maria C. Basil
JBJacob S. Brenner
Jacob S. Brenner

11 December 2024 in Advanced Materials
Verified
Journal Article
Open access
MZMichael H. Zaleski
Michael H. Zaleski
LCLiam S. Chase
Liam S. Chase
EHElizabeth D. Hood
Elizabeth D. Hood
ZWZhicheng Wang
Zhicheng Wang
JNJia Nong
Jia Nong
JBJacob S. Brenner
Jacob S. Brenner
Conjugation chemistries are a major enabling technology for the development of drug delivery systems, from antibody‐drug conjugates to antibody‐targeted lipid nanoparticles inspired by the success of the COVID‐19 vaccine. However, here it is shown that for antibody‐targeted nanoparticles, the most popular conjugation chemistries directly participate in the activation of the complement cascade of plasma proteins. Their activation of complement leads to large changes in the biodistribution of nanoparticles (up to 140‐fold increased uptake into phagocytes of the lungs) and multiple toxicities, including a 50% drop in platelet count. It is founded that the mechanism of complement activation varies dramatically between different conjugation chemistries. Dibenzocyclooctyne, a commonly used click‐chemistry, caused aggregation of conjugated antibodies, but only on the surface of nanoparticles (not in bulk solution). By contrast, thiol‐maleimide chemistry do not activate complement via its effects on antibodies, but rather because free maleimide bonded to albumin in plasma, and clustered albumin is then attacked by complement. Using these mechanistic insights, solutions are engineered that reduced the activation of complement for each class of conjugation chemistry. These results highlight that while conjugation chemistry is essential for the future of nanomedicine, it is not innocuous and must be designed with opsonins like complement in mind.

16 October 2018 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
EHElizabeth D. Hood
Elizabeth D. Hood
CGColin Fred Greineder
Colin Fred Greineder
TSTea Shuvaeva
Tea Shuvaeva
LWLandis Walsh
Landis Walsh
CVCarlos H. Villa
Carlos H. Villa
VMVladimir R. Muzykantov
Vladimir R. Muzykantov